APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuraminidase Inhibitor Market Analysis and Forecast 2026-2032

31 December 2025190 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitor Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuraminidase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuraminidase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuraminidase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuraminidase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuraminidase Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuraminidase Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Neuraminidase Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuraminidase Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuraminidase Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neuraminidase Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Neuraminidase Inhibitor Segment by Company

GlaxoSmithKline

Gilead Sciences

F. Hoffman-La Roche

Daiichi Sankyo

BioCryst

Neuraminidase Inhibitor Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitor Segment by Application

Hospital Pharmacies

Drug Stores

Retail Stores

Others

Neuraminidase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neuraminidase Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuraminidase Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuraminidase Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oseltamivir Major Manufacturers Table 3. Laninamivir Major Manufacturers Table 4. Peramivir Major Manufacturers Table 5. Zanamivir Major Manufacturers Table 6. Global Neuraminidase Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Manufacturers Table 8. Drug Stores Major Manufacturers Table 9. Retail Stores Major Manufacturers Table 10. Others Major Manufacturers Table 11. Neuraminidase Inhibitor Industry Trends Table 12. Neuraminidase Inhibitor Industry Drivers Table 13. Neuraminidase Inhibitor Industry Opportunities and Challenges Table 14. Neuraminidase Inhibitor Industry Restraints Table 15. Global Neuraminidase Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Neuraminidase Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Neuraminidase Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Neuraminidase Inhibitor Revenue Market Share by Region (2021-2026) Table 19. Global Neuraminidase Inhibitor Revenue Market Share by Region (2027-2032) Table 20. Global Neuraminidase Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Neuraminidase Inhibitor Sales by Region (2021-2026) & (K Units) Table 22. Global Neuraminidase Inhibitor Sales by Region (2027-2032) & (K Units) Table 23. Global Neuraminidase Inhibitor Sales Market Share by Region (2021-2026) Table 24. Global Neuraminidase Inhibitor Sales Market Share by Region (2027-2032) Table 25. Global Neuraminidase Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Neuraminidase Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Neuraminidase Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Neuraminidase Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 29. Global Neuraminidase Inhibitor Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Neuraminidase Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Neuraminidase Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Neuraminidase Inhibitor Manufacturers, Product Type & Application Table 33. Global Neuraminidase Inhibitor Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Neuraminidase Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Neuraminidase Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2026) Table 40. Global Neuraminidase Inhibitor Revenue Market Share by Type (2027-2032) Table 41. Global Neuraminidase Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 43. Global Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 44. Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2026) Table 45. Global Neuraminidase Inhibitor Sales Market Share by Type (2027-2032) Table 46. Global Neuraminidase Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 47. Global Neuraminidase Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 48. Global Neuraminidase Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2026) Table 52. Global Neuraminidase Inhibitor Revenue Market Share by Application (2027-2032) Table 53. Global Neuraminidase Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 55. Global Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 56. Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2026) Table 57. Global Neuraminidase Inhibitor Sales Market Share by Application (2027-2032) Table 58. Global Neuraminidase Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 59. Global Neuraminidase Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 60. GlaxoSmithKline Company Information Table 61. GlaxoSmithKline Business Overview Table 62. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio Table 64. GlaxoSmithKline Recent Development Table 65. Gilead Sciences Company Information Table 66. Gilead Sciences Business Overview Table 67. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Gilead Sciences Neuraminidase Inhibitor Product Portfolio Table 69. Gilead Sciences Recent Development Table 70. F. Hoffman-La Roche Company Information Table 71. F. Hoffman-La Roche Business Overview Table 72. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio Table 74. F. Hoffman-La Roche Recent Development Table 75. Daiichi Sankyo Company Information Table 76. Daiichi Sankyo Business Overview Table 77. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio Table 79. Daiichi Sankyo Recent Development Table 80. BioCryst Company Information Table 81. BioCryst Business Overview Table 82. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. BioCryst Neuraminidase Inhibitor Product Portfolio Table 84. BioCryst Recent Development Table 85. North America Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 88. North America Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 89. North America Neuraminidase Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 90. North America Neuraminidase Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 91. North America Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 92. North America Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 93. North America Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 94. North America Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 95. North America Neuraminidase Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 96. North America Neuraminidase Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 97. North America Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Neuraminidase Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 99. North America Neuraminidase Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 100. North America Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 101. North America Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 102. North America Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 103. North America Neuraminidase Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 104. North America Neuraminidase Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 105. United States Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 106. Canada Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 107. Europe Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 110. Europe Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 111. Europe Neuraminidase Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 112. Europe Neuraminidase Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 113. Europe Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 116. Europe Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 117. Europe Neuraminidase Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 118. Europe Neuraminidase Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 119. Europe Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Neuraminidase Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. Europe Neuraminidase Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. Europe Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 123. Europe Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 124. Europe Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 125. Europe Neuraminidase Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 126. Europe Neuraminidase Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 127. Germany Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 128. France Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 129. U.K. Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 130. Italy Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 131. Netherlands Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 132. China Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 133. China Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 134. China Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 135. China Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 136. China Neuraminidase Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 137. China Neuraminidase Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 138. China Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 139. China Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 140. China Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 141. China Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 142. China Neuraminidase Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 143. China Neuraminidase Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 144. Asia Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 145. Asia Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 146. Asia Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 147. Asia Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 148. Asia Neuraminidase Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 149. Asia Neuraminidase Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 150. Asia Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 151. Asia Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 152. Asia Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 153. Asia Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 154. Asia Neuraminidase Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 155. Asia Neuraminidase Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 156. Asia Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Asia Neuraminidase Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 158. Asia Neuraminidase Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 159. Asia Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 160. Asia Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 161. Asia Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 162. Asia Neuraminidase Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 163. Asia Neuraminidase Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 164. Japan Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 165. South Korea Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 166. India Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 167. Australia Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 168. China Taiwan Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 169. Southeast Asia Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 170. SAMEA Neuraminidase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 171. SAMEA Neuraminidase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 172. SAMEA Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 173. SAMEA Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 174. SAMEA Neuraminidase Inhibitor Sales Price by Type (2021-2026) & (US$/Unit) Table 175. SAMEA Neuraminidase Inhibitor Sales Price by Type (2027-2032) & (US$/Unit) Table 176. SAMEA Neuraminidase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 177. SAMEA Neuraminidase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 178. SAMEA Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 179. SAMEA Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 180. SAMEA Neuraminidase Inhibitor Sales Price by Application (2021-2026) & (US$/Unit) Table 181. SAMEA Neuraminidase Inhibitor Sales Price by Application (2027-2032) & (US$/Unit) Table 182. SAMEA Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. SAMEA Neuraminidase Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. SAMEA Neuraminidase Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. SAMEA Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 186. SAMEA Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 187. SAMEA Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 188. SAMEA Neuraminidase Inhibitor Sales Price by Country (2021-2026) & (US$/Unit) Table 189. SAMEA Neuraminidase Inhibitor Sales Price by Country (2027-2032) & (US$/Unit) Table 190. Brazil Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 191. Argentina Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 192. Chile Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 193. Colombia Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 194. Peru Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 195. Saudi Arabia Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 196. Israel Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 197. UAE Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 198. Turkey Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 199. Iran Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 200. Egypt Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Neuraminidase Inhibitor Distributors List Table 204. Neuraminidase Inhibitor Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitor Image Figure 2. Global Neuraminidase Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuraminidase Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oseltamivir Image Figure 5. Laninamivir Image Figure 6. Peramivir Image Figure 7. Zanamivir Image Figure 8. Global Neuraminidase Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neuraminidase Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Drug Stores Image Figure 12. Retail Stores Image Figure 13. Others Image Figure 14. Global Neuraminidase Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neuraminidase Inhibitor Revenue (2021-2032) & (US$ Million) Figure 16. Global Neuraminidase Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Neuraminidase Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Neuraminidase Inhibitor Revenue Market Share by Region (2021-2032) Figure 19. Global Neuraminidase Inhibitor Sales (2021-2032) & (K Units) Figure 20. Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Neuraminidase Inhibitor Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Neuraminidase Inhibitor Sales YoY (2021-2032) & (K Units) Figure 23. Europe Neuraminidase Inhibitor Sales YoY (2021-2032) & (K Units) Figure 24. China Neuraminidase Inhibitor Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Neuraminidase Inhibitor Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Neuraminidase Inhibitor Sales YoY (2021-2032) & (K Units) Figure 27. Global Neuraminidase Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Neuraminidase Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Neuraminidase Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Neuraminidase Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2032) Figure 33. Global Neuraminidase Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Neuraminidase Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2032) Figure 36. Global Neuraminidase Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Neuraminidase Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2032) Figure 39. Global Neuraminidase Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Neuraminidase Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2032) Figure 42. North America Neuraminidase Inhibitor Revenue Share by Type (2021-2032) Figure 43. North America Neuraminidase Inhibitor Sales Share by Type (2021-2032) Figure 44. North America Neuraminidase Inhibitor Revenue Share by Application (2021-2032) Figure 45. North America Neuraminidase Inhibitor Sales Share by Application (2021-2032) Figure 46. North America Neuraminidase Inhibitor Revenue Share by Country (2021-2032) Figure 47. North America Neuraminidase Inhibitor Sales Share by Country (2021-2032) Figure 48. Europe Neuraminidase Inhibitor Revenue Share by Type (2021-2032) Figure 49. Europe Neuraminidase Inhibitor Sales Share by Type (2021-2032) Figure 50. Europe Neuraminidase Inhibitor Revenue Share by Application (2021-2032) Figure 51. Europe Neuraminidase Inhibitor Sales Share by Application (2021-2032) Figure 52. Europe Neuraminidase Inhibitor Revenue Share by Country (2021-2032) Figure 53. Europe Neuraminidase Inhibitor Sales Share by Country (2021-2032) Figure 54. China Neuraminidase Inhibitor Revenue Share by Type (2021-2032) Figure 55. China Neuraminidase Inhibitor Sales Share by Type (2021-2032) Figure 56. China Neuraminidase Inhibitor Revenue Share by Application (2021-2032) Figure 57. China Neuraminidase Inhibitor Sales Share by Application (2021-2032) Figure 58. Asia Neuraminidase Inhibitor Revenue Share by Type (2021-2032) Figure 59. Asia Neuraminidase Inhibitor Sales Share by Type (2021-2032) Figure 60. Asia Neuraminidase Inhibitor Revenue Share by Application (2021-2032) Figure 61. Asia Neuraminidase Inhibitor Sales Share by Application (2021-2032) Figure 62. Asia Neuraminidase Inhibitor Revenue Share by Country (2021-2032) Figure 63. Asia Neuraminidase Inhibitor Sales Share by Country (2021-2032) Figure 64. SAMEA Neuraminidase Inhibitor Revenue Share by Type (2021-2032) Figure 65. SAMEA Neuraminidase Inhibitor Sales Share by Type (2021-2032) Figure 66. SAMEA Neuraminidase Inhibitor Revenue Share by Application (2021-2032) Figure 67. SAMEA Neuraminidase Inhibitor Sales Share by Application (2021-2032) Figure 68. SAMEA Neuraminidase Inhibitor Revenue Share by Country (2021-2032) Figure 69. SAMEA Neuraminidase Inhibitor Sales Share by Country (2021-2032) Figure 70. Neuraminidase Inhibitor Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Neuraminidase Inhibitor Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Retail Stores
  • Others
Companies covered
  • GlaxoSmithKline
  • Gilead Sciences
  • F. Hoffman-La Roche
  • Daiichi Sankyo
  • BioCryst

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuraminidase Inhibitor Market by Type
  3. 1.2.1 Global Neuraminidase Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oseltamivir
  5. 1.2.3 Laninamivir
  6. 1.2.4 Peramivir
  7. 1.2.5 Zanamivir
  8. 1.3 Neuraminidase Inhibitor Market by Application
  9. 1.3.1 Global Neuraminidase Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Drug Stores
  12. 1.3.4 Retail Stores
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Neuraminidase Inhibitor Market Dynamics
  1. 2.1 Neuraminidase Inhibitor Industry Trends
  2. 2.2 Neuraminidase Inhibitor Industry Drivers
  3. 2.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neuraminidase Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neuraminidase Inhibitor Revenue by Region
  3. 3.2.1 Global Neuraminidase Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuraminidase Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global Neuraminidase Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global Neuraminidase Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neuraminidase Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neuraminidase Inhibitor Sales by Region
  9. 3.4.1 Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neuraminidase Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global Neuraminidase Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global Neuraminidase Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neuraminidase Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global Neuraminidase Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neuraminidase Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neuraminidase Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuraminidase Inhibitor Sales by Manufacturers
  6. 4.2.1 Global Neuraminidase Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neuraminidase Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neuraminidase Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neuraminidase Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neuraminidase Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neuraminidase Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neuraminidase Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global Neuraminidase Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neuraminidase Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 Neuraminidase Inhibitor Tier 1, Tier 2, and Tier 3
5 Neuraminidase Inhibitor Market by Type
  1. 5.1 Global Neuraminidase Inhibitor Revenue by Type
  2. 5.1.1 Global Neuraminidase Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neuraminidase Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neuraminidase Inhibitor Sales by Type
  6. 5.2.1 Global Neuraminidase Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuraminidase Inhibitor Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neuraminidase Inhibitor Price by Type
6 Neuraminidase Inhibitor Market by Application
  1. 6.1 Global Neuraminidase Inhibitor Revenue by Application
  2. 6.1.1 Global Neuraminidase Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neuraminidase Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neuraminidase Inhibitor Sales by Application
  6. 6.2.1 Global Neuraminidase Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neuraminidase Inhibitor Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neuraminidase Inhibitor Price by Application
7 Company Profiles
  1. 7.1 GlaxoSmithKline
  2. 7.1.1 GlaxoSmithKline Company Information
  3. 7.1.2 GlaxoSmithKline Business Overview
  4. 7.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
  6. 7.1.5 GlaxoSmithKline Recent Developments
  7. 7.2 Gilead Sciences
  8. 7.2.1 Gilead Sciences Company Information
  9. 7.2.2 Gilead Sciences Business Overview
  10. 7.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
  12. 7.2.5 Gilead Sciences Recent Developments
  13. 7.3 F. Hoffman-La Roche
  14. 7.3.1 F. Hoffman-La Roche Company Information
  15. 7.3.2 F. Hoffman-La Roche Business Overview
  16. 7.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
  18. 7.3.5 F. Hoffman-La Roche Recent Developments
  19. 7.4 Daiichi Sankyo
  20. 7.4.1 Daiichi Sankyo Company Information
  21. 7.4.2 Daiichi Sankyo Business Overview
  22. 7.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
  24. 7.4.5 Daiichi Sankyo Recent Developments
  25. 7.5 BioCryst
  26. 7.5.1 BioCryst Company Information
  27. 7.5.2 BioCryst Business Overview
  28. 7.5.3 BioCryst Neuraminidase Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
  30. 7.5.5 BioCryst Recent Developments
8 North America
  1. 8.1 North America Neuraminidase Inhibitor Market Size by Type
  2. 8.1.1 North America Neuraminidase Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America Neuraminidase Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America Neuraminidase Inhibitor Price by Type (2021-2032)
  5. 8.2 North America Neuraminidase Inhibitor Market Size by Application
  6. 8.2.1 North America Neuraminidase Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America Neuraminidase Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America Neuraminidase Inhibitor Price by Application (2021-2032)
  9. 8.3 North America Neuraminidase Inhibitor Market Size by Country
  10. 8.3.1 North America Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neuraminidase Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Neuraminidase Inhibitor Market Size by Type
  2. 9.1.1 Europe Neuraminidase Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neuraminidase Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe Neuraminidase Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe Neuraminidase Inhibitor Market Size by Application
  6. 9.2.1 Europe Neuraminidase Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neuraminidase Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe Neuraminidase Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe Neuraminidase Inhibitor Market Size by Country
  10. 9.3.1 Europe Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neuraminidase Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Neuraminidase Inhibitor Market Size by Type
  2. 10.1.1 China Neuraminidase Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China Neuraminidase Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China Neuraminidase Inhibitor Price by Type (2021-2032)
  5. 10.2 China Neuraminidase Inhibitor Market Size by Application
  6. 10.2.1 China Neuraminidase Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China Neuraminidase Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China Neuraminidase Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuraminidase Inhibitor Market Size by Type
  2. 11.1.1 Asia Neuraminidase Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neuraminidase Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia Neuraminidase Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia Neuraminidase Inhibitor Market Size by Application
  6. 11.2.1 Asia Neuraminidase Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neuraminidase Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia Neuraminidase Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia Neuraminidase Inhibitor Market Size by Country
  10. 11.3.1 Asia Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neuraminidase Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuraminidase Inhibitor Market Size by Type
  2. 12.1.1 SAMEA Neuraminidase Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neuraminidase Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neuraminidase Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA Neuraminidase Inhibitor Market Size by Application
  6. 12.2.1 SAMEA Neuraminidase Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neuraminidase Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neuraminidase Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA Neuraminidase Inhibitor Market Size by Country
  10. 12.3.1 SAMEA Neuraminidase Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neuraminidase Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neuraminidase Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neuraminidase Inhibitor Value Chain Analysis
  2. 13.1.1 Neuraminidase Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neuraminidase Inhibitor Production Mode & Process
  6. 13.2 Neuraminidase Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neuraminidase Inhibitor Distributors
  9. 13.2.3 Neuraminidase Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst